Cargando…

Magnesium isoglycyrrhizinate prevents the nonalcoholic hepatic steatosis via regulating energy homeostasis

Non‐alcoholic fatty liver disease is a public health problem worldwide associated with high morbidity and hepatic steatosis, but no effective therapeutic interventions. Magnesium isoglycyrrhizinate (MGIG), a derivative of an active component of Glycyrrhiza glabra, is widely used for the treatment of...

Descripción completa

Detalles Bibliográficos
Autores principales:	Jiang, Wenjiao, Xu, Shiyu, Guo, Huijie, Lu, Li, Liu, Jie, Wang, Guangji, Hao, Kun
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2020
Materias:	Original Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7339216/ https://www.ncbi.nlm.nih.gov/pubmed/32410294 http://dx.doi.org/10.1111/jcmm.15230

Ejemplares similares

Magnesium Isoglycyrrhizinate Reduces Hepatic Lipotoxicity through Regulating Metabolic Abnormalities
por: Lu, Li, et al.
Publicado: (2021)

Magnesium isoglycyrrhizinate shows hepatoprotective effects in a cyclophosphamide-induced model of hepatic injury
por: Jiang, Wenjiao, et al.
Publicado: (2017)

Magnesium isoglycyrrhizinate attenuates acute alcohol-induced hepatic steatosis in a zebrafish model by regulating lipid metabolism and ER stress
por: Dai, Wencong, et al.
Publicado: (2022)

Protective Effect of Magnesium Isoglycyrrhizinate on Ethanol-Induced Testicular Injuries in Mice
por: He, Yuanqiao, et al.
Publicado: (2010)

Magnesium Isoglycyrrhizinate Reduces the Target-Binding Amount of Cisplatin to Mitochondrial DNA and Renal Injury through SIRT3
por: Wang, Xinyu, et al.
Publicado: (2022)

Amelioration of Ethanol-Induced Hepatitis by Magnesium Isoglycyrrhizinate through Inhibition of Neutrophil Cell Infiltration and Oxidative Damage
por: Wang, Yan, et al.
Publicado: (2017)

Magnesium isoglycyrrhizinate has hepatoprotective effects in an oxaliplatin-induced model of liver injury
por: Zou, Xueqing, et al.
Publicado: (2018)

Magnesium isoglycyrrhizinate inhibits airway inflammation in rats with chronic obstructive pulmonary disease
por: Yang, Ye, et al.
Publicado: (2021)

Magnesium Isoglycyrrhizinate Ameliorates Concanavalin A-Induced Liver Injury by Inhibiting Autophagy
por: Fan, Zihao, et al.
Publicado: (2022)

Efficacy of salmeterol and magnesium isoglycyrrhizinate combination treatment in rats with chronic obstructive pulmonary disease
por: Yang, Ye, et al.
Publicado: (2022)

Magnesium Isoglycyrrhizinate Ameliorates Fibrosis and Disrupts TGF-β-Mediated SMAD Pathway in Activated Hepatic Stellate Cell Line LX2
por: Tee, Jie Kai, et al.
Publicado: (2018)

Nephroprotective effect of magnesium isoglycyrrhizinate against arsenic trioxide-induced acute kidney damage in mice
por: Wei, Ziheng, et al.
Publicado: (2022)

Amelioration of concanavalin A-induced autoimmune hepatitis by magnesium isoglycyrrhizinate through inhibition of CD4(+)CD25(−)CD69(+) subset proliferation
por: Yang, Qi, et al.
Publicado: (2016)

Licorice root extract and magnesium isoglycyrrhizinate protect against triptolide-induced hepatotoxicity via up-regulation of the Nrf2 pathway
por: Tan, Qin-You, et al.
Publicado: (2018)

Exploration of the hepatoprotective effect and mechanism of magnesium isoglycyrrhizinate in mice with arsenic trioxide-induced acute liver injury
por: Liu, Miaomiao, et al.
Publicado: (2021)

Magnesium Isoglycyrrhizinate Induces an Inhibitory Effect on Progression and Epithelial–Mesenchymal Transition of Laryngeal Cancer via the NF-κB/Twist Signaling
por: Zhang, Jiarui, et al.
Publicado: (2020)

Dataset on assessment of magnesium isoglycyrrhizinate injection for dairy diet and body weight in fructose-induced metabolic syndrome of rats
por: Zhao, Xiao-Juan, et al.
Publicado: (2018)

Magnesium isoglycyrrhizinate suppresses bladder cancer progression by modulating the miR-26b/Nox4 axis
por: Yuan, Zhihao, et al.
Publicado: (2022)

Modulation of Gut Microbiota by Magnesium Isoglycyrrhizinate Mediates Enhancement of Intestinal Barrier Function and Amelioration of Methotrexate-Induced Liver Injury
por: Xia, Yawen, et al.
Publicado: (2022)

Erratum: Modulation of Gut Microbiota by Magnesium Isoglycyrrhizinate Mediates Enhancement of Intestinal Barrier Function and Amelioration of Methotrexate-Induced Liver Injury
Publicado: (2022)

Association of the Nonalcoholic Hepatic Steatosis and Its Degrees With the Values of Liver Enzymes and Homeostasis Model Assessment-Insulin Resistance Index
por: Cruz, Mario Augusto Ferreira, et al.
Publicado: (2015)

Magnesium Isoglycyrrhizinate Alleviates Arsenic Trioxide-Induced Cardiotoxicity: Contribution of Nrf2 and TLR4/NF-κB Signaling Pathway
por: Zheng, Bin, et al.
Publicado: (2021)

Nonalcoholic fatty liver disease: molecular mechanisms for the hepatic steatosis
por: Koo, Seung-Hoi
Publicado: (2013)

A noninvasive diagnostic model to assess nonalcoholic hepatic steatosis in patients with chronic hepatitis B
por: Ou, Hongjie, et al.
Publicado: (2016)

Prevention of Nonalcoholic Hepatic Steatosis by Shenling Baizhu Powder: Involvement of Adiponectin-Induced Inhibition of Hepatic SREBP-1c
por: Tang, Kairui, et al.
Publicado: (2020)

Nonalcoholic Fatty Liver Disease: Noninvasive Methods of Diagnosing Hepatic Steatosis
por: AlShaalan, Rasha, et al.
Publicado: (2015)

Hepatic Steatosis in Infancy: The Beginning of Pediatric Nonalcoholic Fatty Liver Disease?
por: McNelis, Kera, et al.
Publicado: (2021)

Effect of a ketogenic diet on hepatic steatosis and hepatic mitochondrial metabolism in nonalcoholic fatty liver disease
por: Luukkonen, Panu K., et al.
Publicado: (2020)

Inhibition of Plasminogen Activator Inhibitor 1 Attenuates Hepatic Steatosis but Does Not Prevent Progressive Nonalcoholic Steatohepatitis in Mice
por: Henkel, Anne S., et al.
Publicado: (2018)

Ezetimibe decreased nonalcoholic fatty liver disease activity score but not hepatic steatosis
por: Lee, Hyo Young, et al.
Publicado: (2019)

Sulforaphane Attenuates Nonalcoholic Fatty Liver Disease by Inhibiting Hepatic Steatosis and Apoptosis
por: Li, Jinwang, et al.
Publicado: (2021)

IMM‐H007, a new therapeutic candidate for nonalcoholic fatty liver disease, improves hepatic steatosis in hamsters fed a high‐fat diet
por: Shi, Huijie, et al.
Publicado: (2017)

L-theanine prevents progression of nonalcoholic hepatic steatosis by regulating hepatocyte lipid metabolic pathways via the CaMKKβ-AMPK signaling pathway
por: Liang, Juanjuan, et al.
Publicado: (2022)

Ginsenosides Improve Nonalcoholic Fatty Liver Disease via Integrated Regulation of Gut Microbiota, Inflammation and Energy Homeostasis
por: Liang, Wenyi, et al.
Publicado: (2021)

Lipopolysaccharides accelerate hepatic steatosis in the development of nonalcoholic fatty liver disease in Zucker rats
por: Fukunishi, Shinya, et al.
Publicado: (2014)

Quantitative ultrasound approaches for diagnosis and monitoring hepatic steatosis in nonalcoholic fatty liver disease
por: Pirmoazen, Amir M., et al.
Publicado: (2020)

Change in skeletal muscle mass is associated with hepatic steatosis in nonalcoholic fatty liver disease
por: Jo, Ik Hyun, et al.
Publicado: (2023)

Dietary α-linolenic acid-rich flaxseed oil prevents against alcoholic hepatic steatosis via ameliorating lipid homeostasis at adipose tissue-liver axis in mice
por: Wang, Meng, et al.
Publicado: (2016)

Does Nonalcoholic Pancreatic Steatosis Always Correlate with Nonalcoholic Fatty Liver Disease?
por: Ulasoglu, Celal, et al.
Publicado: (2021)

Magnesium Isoglycyrrhizinate Attenuates Anti-Tuberculosis Drug-Induced Liver Injury by Enhancing Intestinal Barrier Function and Inhibiting the LPS/TLRs/NF-κB Signaling Pathway in Mice
por: Gong, Jin-Yu, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_3f8rqme1nr0263lksa7v32583d